Wei Gao

ORCID: 0000-0003-3541-9568 · 6 papers in corpus
preprint 2025
·doi:10.21203/rs.3.rs-7601608/v1

Abstract Background : Incarcerated gravid uterus (IGU), which is characterized by entrapment of the retroverted uterus within the pelvis during the gestational period, is an uncommon condition but might potentially lead to serious mater…

2025
·doi:10.21203/rs.3.rs-8093350/v1

Abstract As quantum communication networks approach practical deployment, mediated semi-quantum key distribution (MSQKD) has attracted attention for enabling classical users to share keys via semi-honest servers. This paper proposes a cros…

other 2025
BMC public health ·doi:10.1186/s12889-025-21576-z

OBJECTIVE: Little is known about the role of timing of physical activity in female reproductive disorders. These disorders include polycystic ovary syndrome (PCOS), heavy menstrual bleeding (HMB), endometriosis, infertility, and pregnancy-r…

article 2022
British journal of clinical pharmacology ·doi:10.1111/bcp.15440

AIM: Elagolix, a gonadotropin-releasing hormone receptor antagonist, was recently approved for heavy menstrual bleeding associated with uterine fibroids (UF, Oriahnn) at a dose of 300 mg twice daily (BID) in combination with add-back therap…

peer-review 2020
·doi:10.1002/jbm4.10401/v2/response1
article 2020
JBMR plus ·doi:10.1002/jbm4.10401

ABSTRACT Elagolix, a gonadotrophin‐releasing hormone antagonist, is used in premenopausal women with endometriosis. There is a risk of bone loss with elagolix, but the long‐term effects of BMD loss later in life cannot be directly assessed …